Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envarsus and Everolimus in Elderly De-novo Kidney Transplant Recipients
NCT02970630Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jan 2017
- Primary completion
- Feb 2018
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tacrolimus in kidney transplant rejection, sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Tacrolimus Area Under the curve at 24 hours, Tacrolimus Minimum whole blood concentration at 10 days and 2 more. Started Jan 2017; status: completed.
02
Drugs
tacrolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT02970630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02970630.